These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1111 related articles for article (PubMed ID: 8613958)
1. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958 [TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. Wells JL; Bartlett JL; Ananthan S; Bilsky EJ J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048 [TBL] [Abstract][Full Text] [Related]
3. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay. Sterious SN; Walker EA J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605 [TBL] [Abstract][Full Text] [Related]
4. Precipitation of spinally mediated withdrawal signs by intrathecal administration of naloxone and the mu-receptor antagonist CTP in morphine-dependent mice. Shook J; Kazmierski W; Hruby V; Burks T NIDA Res Monogr; 1988; 81():143-8. PubMed ID: 2900467 [TBL] [Abstract][Full Text] [Related]
6. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens. Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831 [TBL] [Abstract][Full Text] [Related]
7. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors. Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541 [TBL] [Abstract][Full Text] [Related]
8. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord. He L; Lee NM J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421 [TBL] [Abstract][Full Text] [Related]
9. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells. Zadina JE; Harrison LM; Ge LJ; Kastin AJ; Chang SL J Pharmacol Exp Ther; 1994 Sep; 270(3):1086-96. PubMed ID: 7932156 [TBL] [Abstract][Full Text] [Related]
10. Blocking mu opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioids. Chen SR; Pan HL Brain Res; 2006 Apr; 1081(1):119-25. PubMed ID: 16499888 [TBL] [Abstract][Full Text] [Related]
11. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. Abbruscato TJ; Thomas SA; Hruby VJ; Davis TP J Pharmacol Exp Ther; 1997 Jan; 280(1):402-9. PubMed ID: 8996221 [TBL] [Abstract][Full Text] [Related]
12. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons. Chieng B; Connor M; Christie MJ Mol Pharmacol; 1996 Sep; 50(3):650-5. PubMed ID: 8794906 [TBL] [Abstract][Full Text] [Related]
14. Reversal of morphine antinociceptive tolerance and dependence by the acute supraspinal inhibition of Ca(2+)/calmodulin-dependent protein kinase II. Tang L; Shukla PK; Wang LX; Wang ZJ J Pharmacol Exp Ther; 2006 May; 317(2):901-9. PubMed ID: 16505162 [TBL] [Abstract][Full Text] [Related]
15. Repeated administration of nicotine attenuates the development of morphine tolerance and dependence in mice. Haghparast A; Khani A; Naderi N; Alizadeh AM; Motamedi F Pharmacol Biochem Behav; 2008 Feb; 88(4):385-92. PubMed ID: 17915302 [TBL] [Abstract][Full Text] [Related]
16. Opioid agonist and antagonist antinociceptive properties of [D-Ala2,Leu5,Cys6]enkephalin: selective actions at the deltanoncomplexed site. Qi JA; Bowen WD; Mosberg HI; Rothman RB; Porreca F J Pharmacol Exp Ther; 1990 Nov; 255(2):636-41. PubMed ID: 2173752 [TBL] [Abstract][Full Text] [Related]
18. DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens. Al-Khrasani M; Spetea M; Friedmann T; Riba P; Király K; Schmidhammer H; Furst S Brain Res Bull; 2007 Oct; 74(5):369-75. PubMed ID: 17845912 [TBL] [Abstract][Full Text] [Related]
19. Involvement of supraspinal epsilon and mu opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse. Xu JY; Fujimoto JM; Tseng LF J Pharmacol Exp Ther; 1992 Oct; 263(1):246-52. PubMed ID: 1328609 [TBL] [Abstract][Full Text] [Related]
20. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling. Szücs M; Boda K; Gintzler AR J Pharmacol Exp Ther; 2004 Jul; 310(1):256-62. PubMed ID: 14996951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]